Relativity 股東批准與 Instinct Bio Technical 的合併案
Relativity Shareholders Approve Merger with Instinct Bio Technical
2026年3月24日，Relativity Acquisition Corp.
On March 24, 2026, shareholders of Relativity Acquisition Corp.
(OTC: ACQC) 的股東正式投票通過了與日本Instinct Bio Technical Company Inc.
(OTC: ACQC) officially voted to approve a business combination with the Japanese firm Instinct Bio Technical Company Inc.
這項價值約2.42億美元的合併案，讓這家再生醫學公司得以公開上市，並將其股票轉移至NASDAQ交易所，股票代號為「BIOT」。
Founded in 2017, Instinct Bio Technical distinguishes itself through a vertically integrated business model that controls the entire lifecycle of its stem cell-based skincare and wellness products.
Instinct Bio Technical成立於2017年，其特點在於擁有垂直整合的商業模式，能控管其幹細胞護膚與健康產品的整個生命週期。
Tomoki Nagano, the founder of the company, will lead the combined entity as it aims for international expansion.
公司創辦人Tomoki Nagano將領導合併後的實體，目標是進行國際擴張。
The firm plans to use the capital raised from this public listing to scale its operations, including building new facilities in Japan and introducing its unique clinic model into markets like Malaysia and Indonesia.
該公司計畫利用此次公開上市籌集的資金來擴大營運規模，包括在日本建立新設施，並將其獨特的診所模式引入馬來西亞與印尼等市場。
This deal marks a significant milestone in the sector, as it bridges the gap between high-end regenerative science and the growing consumer wellness market.
雖然該合併案預計在未來幾週內完成，但此次股東投票的成功，象徵著該公司朝向成為幹細胞產業全球領導者的目標邁進了一大步。
